JP2017527616A5

JP2017527616A5 -

Download PDF

Info

Publication number: JP2017527616A5
Authority: JP; Japan
Prior art keywords: nrp1; trap; seq; sema3a; domain
Prior art date: 2015-09-08
Legal status : Granted

Application number

JP2017531928A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017527616A (ja

JP6692816B2 (ja

Filing date

2015-09-08

Publication date

2018-10-18

2015-09-08 Application filed filed Critical

2015-09-08 Priority claimed from PCT/CA2015/050862 external-priority patent/WO2016033699A1/en

2017-09-21 Publication of JP2017527616A publication Critical patent/JP2017527616A/ja

2018-10-18 Publication of JP2017527616A5 publication Critical patent/JP2017527616A5/ja

2020-05-13 Application granted granted Critical

2020-05-13 Publication of JP6692816B2 publication Critical patent/JP6692816B2/ja

Status Active legal-status Critical Current

2035-09-08 Anticipated expiration legal-status Critical

Links

102000004207 Neuropilin-1 Human genes 0.000 claims description 663
108090000772 Neuropilin-1 Proteins 0.000 claims description 663
108090000765 processed proteins & peptides Proteins 0.000 claims description 170
102000004196 processed proteins & peptides Human genes 0.000 claims description 168
229920001184 polypeptide Polymers 0.000 claims description 165
210000004027 cell Anatomy 0.000 claims description 129
238000000034 method Methods 0.000 claims description 98
125000003275 alpha amino acid group Chemical group 0.000 claims description 59
239000000203 mixture Substances 0.000 claims description 50
150000007523 nucleic acids Chemical class 0.000 claims description 47
206010061218 Inflammation Diseases 0.000 claims description 42
230000004054 inflammatory process Effects 0.000 claims description 42
102000039446 nucleic acids Human genes 0.000 claims description 40
108020004707 nucleic acids Proteins 0.000 claims description 40
230000004068 intracellular signaling Effects 0.000 claims description 39
239000013598 vector Substances 0.000 claims description 33
206010040047 Sepsis Diseases 0.000 claims description 29
108020004459 Small interfering RNA Proteins 0.000 claims description 27
230000001404 mediated effect Effects 0.000 claims description 25
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 22
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 22
230000028327 secretion Effects 0.000 claims description 21
102000004889 Interleukin-6 Human genes 0.000 claims description 13
108090001005 Interleukin-6 Proteins 0.000 claims description 13
230000006378 damage Effects 0.000 claims description 9
239000013604 expression vector Substances 0.000 claims description 6
210000001539 phagocyte Anatomy 0.000 claims description 6
208000027418 Wounds and injury Diseases 0.000 claims description 5
208000014674 injury Diseases 0.000 claims description 4
241000702421 Dependoparvovirus Species 0.000 claims description 3
108091027967 Small hairpin RNA Proteins 0.000 claims description 3
239000013603 viral vector Substances 0.000 claims description 3
239000004055 small Interfering RNA Substances 0.000 claims 1
108010090319 Semaphorin-3A Proteins 0.000 description 183
102000013008 Semaphorin-3A Human genes 0.000 description 183
241000699670 Mus sp. Species 0.000 description 141
210000001525 retina Anatomy 0.000 description 136
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 118
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 117
235000001014 amino acid Nutrition 0.000 description 103
229940024606 amino acid Drugs 0.000 description 101
150000001413 amino acids Chemical class 0.000 description 99
210000002864 mononuclear phagocyte Anatomy 0.000 description 94
101150051337 NRP1 gene Proteins 0.000 description 93
230000027455 binding Effects 0.000 description 83
239000003446 ligand Substances 0.000 description 67
230000000694 effects Effects 0.000 description 59
230000014509 gene expression Effects 0.000 description 59
210000000274 microglia Anatomy 0.000 description 57
241000699666 Mus <mouse, genus> Species 0.000 description 52
150000001875 compounds Chemical class 0.000 description 51
206010012689 Diabetic retinopathy Diseases 0.000 description 43
210000002540 macrophage Anatomy 0.000 description 43
230000002207 retinal effect Effects 0.000 description 40
208000017442 Retinal disease Diseases 0.000 description 36
206010038923 Retinopathy Diseases 0.000 description 36
230000008859 change Effects 0.000 description 35
230000035772 mutation Effects 0.000 description 35
230000002792 vascular Effects 0.000 description 35
108090000623 proteins and genes Proteins 0.000 description 34
239000012634 fragment Substances 0.000 description 33
230000005764 inhibitory process Effects 0.000 description 32
230000002401 inhibitory effect Effects 0.000 description 28
239000002773 nucleotide Substances 0.000 description 28
125000003729 nucleotide group Chemical group 0.000 description 28
239000003981 vehicle Substances 0.000 description 28
206010040070 Septic Shock Diseases 0.000 description 27
230000015788 innate immune response Effects 0.000 description 27
230000007959 normoxia Effects 0.000 description 27
235000018102 proteins Nutrition 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 27
230000036303 septic shock Effects 0.000 description 27
102000004127 Cytokines Human genes 0.000 description 26
108090000695 Cytokines Proteins 0.000 description 26
230000001419 dependent effect Effects 0.000 description 26
108010029485 Protein Isoforms Proteins 0.000 description 25
102000001708 Protein Isoforms Human genes 0.000 description 25
230000001965 increasing effect Effects 0.000 description 25
239000007924 injection Substances 0.000 description 25
238000002347 injection Methods 0.000 description 25
229910052760 oxygen Inorganic materials 0.000 description 24
238000011282 treatment Methods 0.000 description 24
210000001519 tissue Anatomy 0.000 description 23
206010008089 Cerebral artery occlusion Diseases 0.000 description 22
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 22
102100022338 Integrin alpha-M Human genes 0.000 description 22
102000004887 Transforming Growth Factor beta Human genes 0.000 description 22
108090001012 Transforming Growth Factor beta Proteins 0.000 description 22
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 22
210000002798 bone marrow cell Anatomy 0.000 description 22
108020004999 messenger RNA Proteins 0.000 description 22
201000007309 middle cerebral artery infarction Diseases 0.000 description 22
239000001301 oxygen Substances 0.000 description 22
238000006467 substitution reaction Methods 0.000 description 22
230000033115 angiogenesis Effects 0.000 description 21
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 21
208000034038 Pathologic Neovascularization Diseases 0.000 description 20
208000006011 Stroke Diseases 0.000 description 20
230000000692 anti-sense effect Effects 0.000 description 20
230000000302 ischemic effect Effects 0.000 description 20
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 20
241001465754 Metazoa Species 0.000 description 19
238000004519 manufacturing process Methods 0.000 description 19
239000002609 medium Substances 0.000 description 19
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 18
210000004556 brain Anatomy 0.000 description 18
206010012601 diabetes mellitus Diseases 0.000 description 18
238000001943 fluorescence-activated cell sorting Methods 0.000 description 18
230000000770 proinflammatory effect Effects 0.000 description 18
210000001185 bone marrow Anatomy 0.000 description 17
102000005962 receptors Human genes 0.000 description 17
108020003175 receptors Proteins 0.000 description 17
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 16
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 15
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 15
238000003776 cleavage reaction Methods 0.000 description 15
230000009368 gene silencing by RNA Effects 0.000 description 15
102000058223 human VEGFA Human genes 0.000 description 15
208000027866 inflammatory disease Diseases 0.000 description 15
238000000746 purification Methods 0.000 description 15
230000007017 scission Effects 0.000 description 15
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
238000001727 in vivo Methods 0.000 description 14
230000035699 permeability Effects 0.000 description 14
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 13
206010038933 Retinopathy of prematurity Diseases 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 13
230000002950 deficient Effects 0.000 description 13
238000012217 deletion Methods 0.000 description 13
230000037430 deletion Effects 0.000 description 13
238000010586 diagram Methods 0.000 description 13
201000010099 disease Diseases 0.000 description 13
230000001575 pathological effect Effects 0.000 description 13
230000009467 reduction Effects 0.000 description 13
108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
201000006474 Brain Ischemia Diseases 0.000 description 12
206010008120 Cerebral ischaemia Diseases 0.000 description 12
208000022559 Inflammatory bowel disease Diseases 0.000 description 12
108091034117 Oligonucleotide Proteins 0.000 description 12
108091005804 Peptidases Proteins 0.000 description 12
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 12
229910052799 carbon Inorganic materials 0.000 description 12
206010008118 cerebral infarction Diseases 0.000 description 12
210000003161 choroid Anatomy 0.000 description 12
229910052731 fluorine Inorganic materials 0.000 description 12
229910052740 iodine Inorganic materials 0.000 description 12
125000005647 linker group Chemical group 0.000 description 12
238000010172 mouse model Methods 0.000 description 12
230000002265 prevention Effects 0.000 description 12
230000002829 reductive effect Effects 0.000 description 12
230000001225 therapeutic effect Effects 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 11
238000003556 assay Methods 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
239000002502 liposome Substances 0.000 description 11
210000004185 liver Anatomy 0.000 description 11
208000002780 macular degeneration Diseases 0.000 description 11
102100021943 C-C motif chemokine 2 Human genes 0.000 description 10
101710155857 C-C motif chemokine 2 Proteins 0.000 description 10
108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 description 10
102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 10
101000577540 Homo sapiens Neuropilin-1 Proteins 0.000 description 10
206010038934 Retinopathy proliferative Diseases 0.000 description 10
206010064930 age-related macular degeneration Diseases 0.000 description 10
238000009472 formulation Methods 0.000 description 10
230000006870 function Effects 0.000 description 10
230000006698 induction Effects 0.000 description 10
230000008728 vascular permeability Effects 0.000 description 10
208000005590 Choroidal Neovascularization Diseases 0.000 description 9
206010060823 Choroidal neovascularisation Diseases 0.000 description 9
108090001090 Lectins Proteins 0.000 description 9
102000004856 Lectins Human genes 0.000 description 9
102000014105 Semaphorin Human genes 0.000 description 9
108050003978 Semaphorin Proteins 0.000 description 9
230000004913 activation Effects 0.000 description 9
230000007850 degeneration Effects 0.000 description 9
210000003734 kidney Anatomy 0.000 description 9
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
230000009885 systemic effect Effects 0.000 description 9
238000012360 testing method Methods 0.000 description 9
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 8
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 8
101100133721 Caenorhabditis elegans npr-1 gene Proteins 0.000 description 8
208000024248 Vascular System injury Diseases 0.000 description 8
208000012339 Vascular injury Diseases 0.000 description 8
238000009825 accumulation Methods 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000016396 cytokine production Effects 0.000 description 8
229960003699 evans blue Drugs 0.000 description 8
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
230000001771 impaired effect Effects 0.000 description 8
230000002757 inflammatory effect Effects 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
230000011664 signaling Effects 0.000 description 8
238000010186 staining Methods 0.000 description 8
238000001356 surgical procedure Methods 0.000 description 8
208000024827 Alzheimer disease Diseases 0.000 description 7
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
206010061216 Infarction Diseases 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
102000002111 Neuropilin Human genes 0.000 description 7
108050009450 Neuropilin Proteins 0.000 description 7
206010030113 Oedema Diseases 0.000 description 7
238000011529 RT qPCR Methods 0.000 description 7
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
230000002491 angiogenic effect Effects 0.000 description 7
206010003246 arthritis Diseases 0.000 description 7
210000003169 central nervous system Anatomy 0.000 description 7
230000002490 cerebral effect Effects 0.000 description 7
230000035605 chemotaxis Effects 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000007574 infarction Effects 0.000 description 7
238000011813 knockout mouse model Methods 0.000 description 7
239000012528 membrane Substances 0.000 description 7
210000004379 membrane Anatomy 0.000 description 7
201000006417 multiple sclerosis Diseases 0.000 description 7
230000001537 neural effect Effects 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 7
102000040430 polynucleotide Human genes 0.000 description 7
108091033319 polynucleotide Proteins 0.000 description 7
239000002157 polynucleotide Substances 0.000 description 7
238000003753 real-time PCR Methods 0.000 description 7
210000000952 spleen Anatomy 0.000 description 7
229960001052 streptozocin Drugs 0.000 description 7
108010085238 Actins Proteins 0.000 description 6
102000007469 Actins Human genes 0.000 description 6
201000004624 Dermatitis Diseases 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
102000035195 Peptidases Human genes 0.000 description 6
239000004365 Protease Substances 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
208000007135 Retinal Neovascularization Diseases 0.000 description 6
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
108010076818 TEV protease Proteins 0.000 description 6
206010046851 Uveitis Diseases 0.000 description 6
230000007000 age related cognitive decline Effects 0.000 description 6
210000001168 carotid artery common Anatomy 0.000 description 6
230000036755 cellular response Effects 0.000 description 6
238000006471 dimerization reaction Methods 0.000 description 6
210000002889 endothelial cell Anatomy 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
230000012010 growth Effects 0.000 description 6
230000008595 infiltration Effects 0.000 description 6
238000001764 infiltration Methods 0.000 description 6
230000000670 limiting effect Effects 0.000 description 6
230000000926 neurological effect Effects 0.000 description 6
238000006386 neutralization reaction Methods 0.000 description 6
229910052757 nitrogen Inorganic materials 0.000 description 6
239000000047 product Substances 0.000 description 6
235000019833 protease Nutrition 0.000 description 6
235000019419 proteases Nutrition 0.000 description 6
238000011002 quantification Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
206010029113 Neovascularisation Diseases 0.000 description 5
208000028389 Nerve injury Diseases 0.000 description 5
102100028762 Neuropilin-1 Human genes 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
238000007792 addition Methods 0.000 description 5
235000004279 alanine Nutrition 0.000 description 5
230000003698 anagen phase Effects 0.000 description 5
235000003704 aspartic acid Nutrition 0.000 description 5
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
229960002286 clodronic acid Drugs 0.000 description 5
230000003436 cytoskeletal effect Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
235000013922 glutamic acid Nutrition 0.000 description 5
239000004220 glutamic acid Substances 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
229960002725 isoflurane Drugs 0.000 description 5
238000000370 laser capture micro-dissection Methods 0.000 description 5
230000005012 migration Effects 0.000 description 5
238000013508 migration Methods 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000008764 nerve damage Effects 0.000 description 5
210000003024 peritoneal macrophage Anatomy 0.000 description 5
229910052698 phosphorus Inorganic materials 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
230000007115 recruitment Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
230000008685 targeting Effects 0.000 description 5
230000000451 tissue damage Effects 0.000 description 5
231100000827 tissue damage Toxicity 0.000 description 5
231100000216 vascular lesion Toxicity 0.000 description 5
102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 4
102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
102000007260 Deoxyribonuclease I Human genes 0.000 description 4
108010008532 Deoxyribonuclease I Proteins 0.000 description 4
206010061818 Disease progression Diseases 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 description 4
101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 description 4
102100034343 Integrase Human genes 0.000 description 4
208000001344 Macular Edema Diseases 0.000 description 4
206010025415 Macular oedema Diseases 0.000 description 4
101100349097 Mus musculus Nrp1 gene Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
239000000074 antisense oligonucleotide Substances 0.000 description 4
238000012230 antisense oligonucleotides Methods 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
238000005452 bending Methods 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
210000004155 blood-retinal barrier Anatomy 0.000 description 4
230000004378 blood-retinal barrier Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
230000005750 disease progression Effects 0.000 description 4
238000010828 elution Methods 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000012894 fetal calf serum Substances 0.000 description 4
-1 host cell Chemical class 0.000 description 4
102000050920 human NRP1 Human genes 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
239000007928 intraperitoneal injection Substances 0.000 description 4
230000009545 invasion Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
201000010230 macular retinal edema Diseases 0.000 description 4
239000000463 material Substances 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000010232 migration assay Methods 0.000 description 4
230000003472 neutralizing effect Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
238000001742 protein purification Methods 0.000 description 4
230000000250 revascularization Effects 0.000 description 4
108091092562 ribozyme Proteins 0.000 description 4
239000011435 rock Substances 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000002864 sequence alignment Methods 0.000 description 4
238000012546 transfer Methods 0.000 description 4
230000009261 transgenic effect Effects 0.000 description 4
210000005166 vasculature Anatomy 0.000 description 4
210000004127 vitreous body Anatomy 0.000 description 4
238000005406 washing Methods 0.000 description 4
102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
206010002091 Anaesthesia Diseases 0.000 description 3
241000283707 Capra Species 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
208000001351 Epiretinal Membrane Diseases 0.000 description 3
206010015866 Extravasation Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101000632261 Homo sapiens Semaphorin-3A Proteins 0.000 description 3
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 3
206010021143 Hypoxia Diseases 0.000 description 3
241000713666 Lentivirus Species 0.000 description 3
208000031471 Macular fibrosis Diseases 0.000 description 3
101000713935 Mus musculus Tudor domain-containing protein 7 Proteins 0.000 description 3
208000036110 Neuroinflammatory disease Diseases 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 3
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
102000009203 Sema domains Human genes 0.000 description 3
108050000099 Sema domains Proteins 0.000 description 3
108010003723 Single-Domain Antibodies Proteins 0.000 description 3
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000037005 anaesthesia Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
238000001574 biopsy Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
239000002975 chemoattractant Substances 0.000 description 3
230000003399 chemotactic effect Effects 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
230000036251 extravasation Effects 0.000 description 3
239000003889 eye drop Substances 0.000 description 3
229940012356 eye drops Drugs 0.000 description 3
239000000499 gel Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000036039 immunity Effects 0.000 description 3
239000007943 implant Substances 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000003447 ipsilateral effect Effects 0.000 description 3
239000002523 lectin Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
230000022275 macrophage chemotaxis Effects 0.000 description 3
231100000682 maximum tolerated dose Toxicity 0.000 description 3
238000005259 measurement Methods 0.000 description 3
210000004088 microvessel Anatomy 0.000 description 3
210000003657 middle cerebral artery Anatomy 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
150000004713 phosphodiesters Chemical class 0.000 description 3
230000006461 physiological response Effects 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000013641 positive control Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000002062 proliferating effect Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
230000010410 reperfusion Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
210000003994 retinal ganglion cell Anatomy 0.000 description 3
238000010839 reverse transcription Methods 0.000 description 3
239000012679 serum free medium Substances 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000026683 transduction Effects 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
230000006459 vascular development Effects 0.000 description 3
238000001262 western blot Methods 0.000 description 3
IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 2
206010002329 Aneurysm Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102100026735 Coagulation factor VIII Human genes 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
101150026192 Crb1 gene Proteins 0.000 description 2
108010041308 Endothelial Growth Factors Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
208000003098 Ganglion Cysts Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101100495074 Mus musculus Ccl2 gene Proteins 0.000 description 2
101100007778 Mus musculus Crb1 gene Proteins 0.000 description 2
206010061309 Neoplasm progression Diseases 0.000 description 2
108091005461 Nucleic proteins Chemical group 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
208000002193 Pain Diseases 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
108010004729 Phycoerythrin Proteins 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
208000002367 Retinal Perforations Diseases 0.000 description 2
206010057430 Retinal injury Diseases 0.000 description 2
108010057163 Ribonuclease III Proteins 0.000 description 2
102000003661 Ribonuclease III Human genes 0.000 description 2
108010085603 SFLLRNPND Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
208000005400 Synovial Cyst Diseases 0.000 description 2
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
208000038016 acute inflammation Diseases 0.000 description 2
230000006022 acute inflammation Effects 0.000 description 2
230000010398 acute inflammatory response Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
108010004469 allophycocyanin Proteins 0.000 description 2
238000002583 angiography Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000005667 attractant Substances 0.000 description 2
230000004009 axon guidance Effects 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
235000011089 carbon dioxide Nutrition 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000034303 cell budding Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000004581 coalescence Methods 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000037416 cystogenesis Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
230000004438 eyesight Effects 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
210000003194 forelimb Anatomy 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
102000057183 human SEMA3A Human genes 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000006882 induction of apoptosis Effects 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
230000006749 inflammatory damage Effects 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000017306 interleukin-6 production Effects 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
230000004807 localization Effects 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
208000029233 macular holes Diseases 0.000 description 2
108010082117 matrigel Proteins 0.000 description 2
230000001617 migratory effect Effects 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
230000007472 neurodevelopment Effects 0.000 description 2
230000003959 neuroinflammation Effects 0.000 description 2
230000002314 neuroinflammatory effect Effects 0.000 description 2
210000002445 nipple Anatomy 0.000 description 2
230000036407 pain Effects 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
230000037361 pathway Effects 0.000 description 2
210000003200 peritoneal cavity Anatomy 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
108091008695 photoreceptors Proteins 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920002704 polyhistidine Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000001023 pro-angiogenic effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000004263 retinal angiogenesis Effects 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000035882 stress Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000009732 tufting Methods 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
230000006433 tumor necrosis factor production Effects 0.000 description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
239000012117 Alexa Fluor 700 Substances 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
238000011814 C57BL/6N mouse Methods 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
101100204059 Caenorhabditis elegans trap-2 gene Proteins 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010010144 Completed suicide Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
241000252212 Danio rerio Species 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012688 Diabetic retinal oedema Diseases 0.000 description 1
241000255925 Diptera Species 0.000 description 1
LTLYEAJONXGNFG-DCAQKATOSA-N E64 Chemical compound NC(=N)NCCCCNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1O[C@@H]1C(O)=O LTLYEAJONXGNFG-DCAQKATOSA-N 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
102000011652 Formyl peptide receptors Human genes 0.000 description 1
108010076288 Formyl peptide receptors Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000219774 Griffonia Species 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101001010783 Homo sapiens Endoribonuclease Proteins 0.000 description 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
101000582320 Homo sapiens Neurogenic differentiation factor 6 Proteins 0.000 description 1
101000654674 Homo sapiens Semaphorin-6A Proteins 0.000 description 1
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
206010058490 Hyperoxia Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
108010061833 Integrases Proteins 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
101710197072 Lectin 1 Proteins 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
102000009065 Netrin-1 Human genes 0.000 description 1
108010074223 Netrin-1 Proteins 0.000 description 1
102100030589 Neurogenic differentiation factor 6 Human genes 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102100028492 Neuropilin-2 Human genes 0.000 description 1
108090000770 Neuropilin-2 Proteins 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
238000013355 OIR mouse model Methods 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
102000000536 PPAR gamma Human genes 0.000 description 1
108010016731 PPAR gamma Proteins 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
241000282376 Panthera tigris Species 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
241000577979 Peromyscus spicilegus Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920000153 Povidone-iodine Polymers 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
101150111584 RHOA gene Proteins 0.000 description 1
230000007022 RNA scission Effects 0.000 description 1
101100080536 Rattus norvegicus Nrp1 gene Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
239000012722 SDS sample buffer Substances 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
102100027974 Semaphorin-3A Human genes 0.000 description 1
101710199445 Semaphorin-3F Proteins 0.000 description 1
102100027751 Semaphorin-3F Human genes 0.000 description 1
102100032795 Semaphorin-6A Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
108091036066 Three prime untranslated region Proteins 0.000 description 1
108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000034698 Vitreous haemorrhage Diseases 0.000 description 1
208000000208 Wet Macular Degeneration Diseases 0.000 description 1
235000010724 Wisteria floribunda Nutrition 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000002877 alkyl aryl group Chemical group 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
125000005122 aminoalkylamino group Chemical group 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000015624 blood vessel development Effects 0.000 description 1
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
229960001736 buprenorphine Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000004640 cellular pathway Effects 0.000 description 1
230000004637 cellular stress Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical compound [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
201000011190 diabetic macular edema Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000004459 forage Substances 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
238000009650 gentamicin protection assay Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
125000000592 heterocycloalkyl group Chemical group 0.000 description 1
239000000710 homodimer Substances 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000037417 hyperactivation Effects 0.000 description 1
230000003345 hyperglycaemic effect Effects 0.000 description 1
230000000222 hyperoxic effect Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000037451 immune surveillance Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004941 influx Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000019189 interleukin-1 beta production Effects 0.000 description 1
238000010212 intracellular staining Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
230000003988 neural development Effects 0.000 description 1
210000005157 neural retina Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000007971 neurological deficit Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
238000012014 optical coherence tomography Methods 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
238000000059 patterning Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000003668 pericyte Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000000649 photocoagulation Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
102000002022 plexin Human genes 0.000 description 1
108050009312 plexin Proteins 0.000 description 1
108010011110 polyarginine Proteins 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000032361 posttranscriptional gene silencing Effects 0.000 description 1
229960001621 povidone-iodine Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
101150059999 pro gene Proteins 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
210000003289 regulatory T cell Anatomy 0.000 description 1
125000006853 reporter group Chemical group 0.000 description 1
238000002271 resection Methods 0.000 description 1
230000004264 retinal detachment Effects 0.000 description 1
210000001116 retinal neuron Anatomy 0.000 description 1
230000004250 retinal swelling Effects 0.000 description 1
230000004233 retinal vasculature Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000007480 sanger sequencing Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
150000003354 serine derivatives Chemical class 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 1
210000002262 tip cell Anatomy 0.000 description 1
230000030968 tissue homeostasis Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000009752 translational inhibition Effects 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000006453 vascular barrier function Effects 0.000 description 1
230000006711 vascular endothelial growth factor production Effects 0.000 description 1
230000006426 vascular sprouting Effects 0.000 description 1
230000007998 vessel formation Effects 0.000 description 1
230000004382 visual function Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
208000000318 vitreous detachment Diseases 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

JP2017531928A 2014-09-05 2015-09-08 炎症を処置および予防するための組成物および方法 Active JP6692816B2 (ja)